From theheart.org on Medscape

Coverage from the

American College of Cardiology (ACC) 2018 Annual Scientific Session

March 10 - 12, 2018; Orlando, Florida

March 10 - 12, 2018 Orlando, Florida
  • Barbershop-Based Healthcare Cuts Hypertension in Blacks An outreach program leveraging the community barbershop made impressive inroads combatting hypertension in black men, who have the highest hypertension-related death rate in the United States.
  • ODYSSEY: Alirocumab Cuts CV Events, All-Cause Death Post-ACS First evidence of survival benefit with PCSK9 inhibitor alirocumab reignites the call for greater access to these expensive drugs for patients not just with ACS but also with stable atherosclerotic CVD.
  • VEST: No Sudden Death Benefit Early Post-MI From LifeVest But defibrillators work by preventing sudden death, so it's a bit of a head-scratcher that all-cause mortality dropped instead for people who used the wearable defibrillator for 90 days after their MI.

Meeting Highlights At A Glance

  • Top News From ACC 2018: Slideshow Top News From ACC 2018: Slideshow Highly anticipated results of the ODYSSEY Outcomes trial of a PCSK9 inhibitor featured prominently at this year's scientific sessions -- and didn't disappoint.

Conference News

Popular News from ACC 2017

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives From ACC

 

Bloggers From The Floor

  • Pharmacists and Barbers on the Cutting Edge of Medicine Dr Mandrola's hands-down favorite study from the 2018 American College of Cardiology meeting showed that a pharmacist-led intervention in black-owned barbershops cut hypertension in black men.
  • Ten Quick Thoughts on ODYSSEY Despite a suggested mortality benefit for the PCSK9 inhibitor alirocumab, in high-risk ACS patients, a return to lipid targets may be the cost-effective lesson from this trial, argues Dr Mandrola.
  • The VEST Trial Failed, and So Did the Press Release The first randomized trial on the wearable cardioverter defibrillator didn't meet its primary endpoint, yet the press release was overly positive.
  • MOMENTUM-3: The Future of the LVAD Is Here and Now A trial showing better outcomes for HeartMate 3 over HeartMate II sends Dr Walton-Shirley down memory lane to recall the patients she has referred for implantation of a left ventricular assist device (LVAD).
  • Another Way to Save a Life: the MANAGE Trial Dr Walton-Shirley was impressed by a study on dabigatran for myocardial injury after noncardiac surgery at the American College of Cardiology Annual Scientific Session.
  • How Want Became Need With ODYSSEY Dr Walton-Shirley would like to prescribe more PCSK9 inhibitors, given positive data from the American College of Cardiology meeting, but the prior authorization process may break her first
 
 

Pre-Meeting Perspective

 

Previous Coverage